Bevacizumab is a widely researched monoclonal antibody that inhibits VEGF-A and has been approved in combination with chemotherapy for the treatment of chemo-naive non–small-cell lung cancer patients (Assoun et al., 2017; Garcia et al., 2020). Here, VEGFA is linked to lung cancer.